drugset
drugset / Trial / NCT02786979

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

NCT02786979 ↗

Phase 4 Terminated 190 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.

Timeline

Start
2010-07
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Beraprost Small molecule — Oral
Background Aspirin Small molecule — Oral

Indications

type 2 diabetes mellitus